Form 4: Agios Pharmaceuticals Director David Scadden Reports Significant Equity Grants and Vesting

Agios Pharmaceuticals, Inc. Director David Scadden has reported the acquisition of common stock, restricted stock units, and stock options through grants and vesting events, increasing his beneficial ownership in the company.

Summary

• David Scadden, a Director at Agios Pharmaceuticals, Inc. (AGIO), reported several transactions increasing his beneficial ownership.
• On June 20, 2025, Mr. Scadden acquired 2,120 shares of common stock at a price of $0, resulting from the vesting of restricted stock units granted on June 20, 2024.
• Following this transaction, Mr. Scadden directly beneficially owns 17,603 shares of common stock.
• On June 18, 2025, Mr. Scadden was granted 2,816 restricted stock units at a price of $0, which are set to vest in full on June 18, 2026.
• Also on June 18, 2025, Mr. Scadden was granted 15,768 stock options with an exercise price of $35.5 per share, which will vest 100% on June 18, 2026, and expire on June 18, 2035.
• The transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer, intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While the transactions are compensation-related and expected, the director's increased beneficial ownership through equity grants and vesting signals continued alignment with shareholder interests and confidence in the company's future, which is generally viewed favorably by investors.

Positives

• A director, David Scadden, has increased his beneficial ownership in Agios Pharmaceuticals through grants of restricted stock units and stock options, signaling continued alignment with shareholder interests.
• The acquisition of common stock through vesting demonstrates the conversion of previously granted equity into direct share ownership.
• The transactions were conducted under a Rule 10b5-1(c) plan, indicating a pre-arranged and transparent approach to insider equity management.

Risks

• The value of the newly acquired restricted stock units and stock options is subject to the future performance and market price fluctuations of Agios Pharmaceuticals' common stock.
• The vesting of restricted stock units and stock options is contingent upon the director's continued service to the company until the specified vesting dates.

Future Outlook

This Form 4 filing does not provide forward-looking statements or guidance regarding the company's financial performance or strategic outlook, focusing solely on insider equity transactions.

Industry Context

This filing is a standard disclosure of insider equity transactions within the biotechnology and pharmaceutical industry, reflecting compensation practices for directors. It does not provide broader industry trends or competitive analysis.

Corporate Governance

Related Party Transactions

• The reported transactions involve a director of Agios Pharmaceuticals, Inc. acquiring company equity, which constitutes a related party transaction as it is between the company and a member of its management/board.

Stakeholder Impact

• Shareholders: The increase in a director's beneficial ownership through equity grants can be interpreted as a positive signal of management's alignment with shareholder interests and confidence in the company's long-term prospects.
• Employees: While not directly impacting all employees, such compensation structures are common for senior leadership and can reflect the company's overall compensation philosophy.

Next Steps

• The shares underlying the restricted stock units granted on June 18, 2025, are expected to vest in full on June 18, 2026.
• The shares underlying the stock options granted on June 18, 2025, are expected to vest 100% on June 18, 2026.

Key Dates

Recommendation

Keywords

Agios Pharmaceuticals, AGIO, SEC Form 4, Insider Transaction, Director Ownership, Restricted Stock Units, Stock Options, Equity Grant, Beneficial Ownership, Rule 10b5-1